anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To provide a medical information processing system and a medical information processing method which effectively perform processing such as learning of artificial intelligence using medical images.SOLUTION: In an artificial intelligence engine 11 of a medical information processing system, a classification processing section 111 classifies a medical image into a preset category on the basis of a database. A selection processing section 112 selects any of categories classified on the basis of medical information. A matching determination section 113 determines whether the classified category matches the selected category. A peculiarity determination section 114 classifies the medical image into a peculiarity category when the classified category does not match the selected category. A classification adjustment section 115 adjusts an operation parameter of the classification processing section on the basis of a medical image group classified into the peculiarity category. A knowledge acquisition section 116 acquires medical knowledge on the basis of a plurality of medical images classified into the peculiarity category. A left-right discrimination section 117 operates when the medical image is an image of a subject eye and determines whether the medical image is an image of a left eye or an image of a right eye.SELECTED DRAWING: Figure 3
<P>PROBLEM TO BE SOLVED: To provide a simple method to keep a solution under low pH for sterilization and to raise pH before injection without adding any composition.  <P>SOLUTION: To solve the problem, a method for preparing a liquid product is described. The method comprises: a process to prepare a product having pH at least similar to a desired final pH level; a process to decrease pH of the product to a level lower than the desired final pH; and a process to raise pH of the product toward the desired final pH level over a stated period by releasing carbon dioxide from the product. Preferably, the method includes a process to add a carbon dioxide generating compound to the product. In one embodiment, a method to prepare medical solution including a step to place the solution in a gas-permeable container and a process to make carbon dioxide permeate from the container until the desired pH is obtained is provided.  <P>COPYRIGHT: (C)2008,JPO&INPIT
These patients are also at a higher risk of the complications of hyponatremia such as brain injury, the main result of acute symptomatic hyponatremia and associated with significant morbidity and mortality. Severe hyponatremia (i.e., a serum sodium concentration \<125 mmol/L) ), if unrecognized in its first stages and left untreated, has a high rate of mortality; for this reason, an accurate clinical assessment must be made, focusing on fluid status, examining the potential etiology, and conducting the appropriate investigations. In approximately 50% of patients, chronic hyponatremia results from inappropriate antidiuretic hormone secretion. Chronic mild hyponatremia is usually asymptomatic and is traditionally regarded as benign. However, it is associated with a lower bone mineral content and density in nearly all regions of the hip, with more pronounced losses in the trochanteric and femoral neck regions. It can also lead to osteoporosis, abnormal gait patterns, cognitive impairment, bone demineralization, respiratory failure, noncardiogenic pulmonary edema, falls, and fractures. Compared to normonatremic individuals, hyponatremic individuals are known to have a longer time from admission to surgery.

Glutamate which is the main excitatory neurotransmitter in our body may play role in implication of hyponatremia on the brain. Cerebrospinal fluid (CSF) sample can be taken while dripling during spinal anathesia for surgical intervention for determination of glutamate
BACKGROUND: Age-associated muscle decline, termed sarcopenia, is a common systemic effect of chronic obstructive pulmonary disease (COPD). Circulating Neurofilament light chain (NfL) levels reflect neuronal degradation and may be relevant to sarcopenia phenotype. However, such an association in COPD patients remains elusive.
METHODS: We investigated male, 60-76 years old controls (n = 50) and COPD patients (n = 139) for plasma NfL levels in relation to sarcopenia and physical capacity markers. We measured handgrip strength (HGS), body composition, and short physical performance battery (SPPB) to evaluate sarcopenia and physical capacity.
RESULTS: COPD patients had higher plasma NfL and lower HGS and SPPB performance than controls. Plasma NfL levels demonstrated negative associations with HGS and gait speed in COPD patients (all p < 0.05). Further, NfL levels were negatively associated with total SPPB scores in controls and patients with advanced COPD (p < 0.05). Plasma NfL also demonstrated an acceptable accuracy in diagnosing sarcopenia in controls (AUC = 0.757, p < 0.05) and COPD (AUC = 0.806, p < 0.05) patients.
CONCLUSION: Collectively, plasma NfL may be helpful in evaluating sarcopenia phenotype and physical capacity in geriatric patients with COPD.
Participants in clinical response to Induction treatment with IV Placebo will receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
An intravenous bolus of 4.1 mCi (150 MBq) ± 10% of \[68Ga\]-Pentixafor will be injected in all participants that will be imaged on a hybrid PET/CT device. Any of the following factors may determine if imaging cannot be performed: tolerance/compliance in the PET/CT scanner; dose availability; dose quality control; availability of the PET/CT scanner or availability of study personnel. \[68Ga\]-Pentixafor uptake dynamics / pharmacokinetics will be evaluated by PET/CT performed with a low-dose CT component used for PET attenuation correction (1-2 mSv). \[68Ga\]-Pentixafor-PET/CT scan duration will be approximately 1.5 hours. Some patients will have two scans.
OSAS is characterised by loud snoring, upper airway obstruction, and occasional apnea during sleep. OSAS may affect at least 4% of the men and 2% of the women in middle-age. In Sweden, prevalence figures of 200 000 have been reported. The mechanisms behind OSAS is not fully explained but functionally impaired upper airways muscles, causing a reduction in tonic and phasic contraction during sleep, are proposed one key explanation. The reduced contractions cause partial or complete occlusion of airflow, which in turn cause oxygen desaturation and sleep fragmentation. Patients commonly report everyday life consequences including loud snoring, sleep disturbances, daytime sleepiness, reduced alertness and concentration, and involvement in motor vehicle accidents. Between 7% and 70% of patients suffer from depression and anxiety (figures vary extensively because of methodological differences in existing studies). Due to cardiovascular consequences, OSAS is also linked to hypertension, myocardial infarction, and stroke. Approximately 75% of patients with severe OSAS carry overweight. First line measures recommended for OSAS are conservative including lifestyle modifications, CPAP, and oral appliances. Current state-of-science concludes that CPAP is best possible evidence-based treatment. Despite the use of life style modification recommendations in terms of physical activity and weight loss in accepted guidelines of OSAS, randomised clinical trials supporting these recommendations are rare. Hence, the value of health behaviour modifications has yet to be established. Research within this area is therefore of major interest and urgency, which has motivated the present study design.
Treatment Period 2: Subjects were admitted to the clinical unit on Day 1. Subjects received multiple (twice daily \[b.i.d.\]) oral doses of bosentan (Tracleer® 1 x 125 mg film coated tablet) approximately 30 minutes before each meal (breakfast and dinner) from Days 1 to 5. On Day 6 after an overnight fast of at least 8 hours, subjects received a single morning dose of bosentan (Tracleer® 1 x 125 mg film coated tablet). Subjects were discharged from the clinical unit on Day 9 (approximately 72 hours after last dosing) barring any medical reasons for an extended clinical stay.
A method for determining a lipid imbalance in a subject is provided. The method includes providing one or more tape strips comprising a skin surface sample obtained from the subject; extracting epidermal lipids; detecting a composition of lipids present in the extracted sample; and comparing the composition of lipids to a control. A difference in the composition of lipids as compared to the control identifies the lipid imbalance in the subject. A method of augmenting a lipid deficiency in skin of a subject, for example to treat or inhibit infection, prevent water loss, improve hydration and restore barrier is also provided. The method includes identifying a deficiency in one or more lipids in a skin sample obtained from the subject; formulating a topical therapeutic composition that contains the one or more lipids, a similar lipid, or a subset thereof; and providing the composition to the subject. Topical formulations for augmenting a lipid deficiency in the skin of a subject are also disclosed.
The application discloses a disease prediction device and equipment, and a symptom information processing method, device and equipment. The disease prediction device acquires the current symptom characteristic set of the user through a first acquisition unit. And acquiring the prior probability of the target disease and the conditional probability of each symptom characteristic under the target disease from the medical knowledge graph through a second acquisition unit. And calculating an evaluation value of the target disease according to the prior probability of the target disease, the conditional probability of each symptom characteristic under the target disease condition and the characteristic value of each symptom characteristic by a first calculation unit. And sequencing all diseases with the estimated values according to the estimated values through a prediction unit, and determining the diseases with the sequenced conditions as predicted diseases corresponding to the current symptom feature set of the user. Disease prediction is carried out based on the medical knowledge graph, model training is not needed by using labeling data, and cost is reduced. And calculating the evaluation value of the target disease by using the prior probability and the conditional probability in the medical knowledge graph, and improving the accuracy of disease prediction.
Currently, there are two methods of treating subtrochanteric femur fractures: intramedullary nailing and extramedullary plate fixation. However, it remains to be seen whether internal or external fixation is the primary treatment for subrotator femur fractures in adults. In this meta-analysis, we reviewed the effects of internal and external fixation on the treatment of subrotator and subrotator fractures. Until July 2023, the researchers have been researching the Cochrane Library, Embase, Web of Science and PubMed, with English as their only language. The aims of the study are as follows: (1) to assess the efficacy of internal and external fixation for the treatment of postoperative wound infections in adult patients with subrotator femur fractures; (2) to assess the efficacy of various types of internal fixation for the treatment of adult patients with subrotator femur fractures, including postoperative complications, infections, and operative time. Meta-analysis showed that there was no significant difference in the treatment of subrotator fracture with internal versus external fixation in terms of wound infections, intra-operative bleeding, length of incision, and operative time were not significantly different. Therefore, more research is needed to support these findings with a number of large, high-quality randomized studies.
Compounds with the formula: ##STR1## in which R 1  and R 2  represent independently, a linear or branched alkyl, cycloalkyl, phenylalkyl or cycloalkylalkyl group. R 1  and R 2  may also represent an alkenyl or alkynyl group. R 1  and R 2  may also represent a group of the formula --R 3  --Z--R 4  in which R 3  represents an alkylene group, on condition that at least 2 carbon atoms separate the nitrogen atom from the group Z; R 4  represents an alkyl group, and Z an atom of oxygen, sulphur or the group >N--R 5 , R 5  representing a hydrogen atom or an alkyl group. R 1  and R 2  may form, with the nitrogen atom to which they are attached, a heterocyclic ring. Ar represents a phenyl, pyridyl or thienyl group, or a substituted phenyl group, A and B representing independently, N or CH--, the group C representing the residue of a benzene or thiophene ring. These compounds can be used as medicaments, in particular, for the various applications of benzodiazepines.
Education and behavioral observation cohort. These participants must sign an informed consent to participate in this part of the study. In addition to all of Tier 1 activities, participants also complete psychological inventories at three time points to measure emotion regulation and burnout, and participate in a semi-structured interview.
Insert the self-made device into the patient's rectum, pump ice-cold saline in to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by controlling the pumping speed of saline.
The present invention relates to a Minglongganbao medicine for treating hepatitis B and a preparation method thereof. The medicine belongs to a traditional Chinese medicine for treating hepatitis B, and is especially suitable for patients with persistent hepatitis B and people in weak health. The medicine comprises medicines for invigorating the spleen and benefiting qi, medicines for invigorating the kidney and nourishing yin, medicines for dispersing stagnated liver qi and regulating the stomach and medicines for clearing heat and detoxifying toxin, wherein the medicines for invigorating the spleen and benefiting qi comprise ginseng. The preparation method of the medicine comprises a preparation method of pills and a preparation method of medicinal powder. For the formula of pills, the dosage is 5 to 60 grams for each time and 2 to 3 times for each day; for the formula of medicinal powder, the dosage is from 5 to 48 grams each time and from 2 to 3 times each day. The Minglongganbao medicine for treating hepatitis B of the present invention has the advantages of obvious effect and high negative conversion rate. The medicine effectively improves the immunity of human bodies, inhibits and clears hepatitis B viruses, improves hepatic functions and promotes the regeneration of liver cells.
The present invention relates to a multifunctional combined medicament which can effectively treat burn, scald, chemical substance scald and skin diseases. The combined medicament contains three main components of kanamycin or amikacin, procaine and fish liver oil, and penicillin, dexamethasone and gentamicin can also be added respectively, or the combination of penicillin, dexamethasone and gentamicin can be added. The weight proportion of the main components is: 0.25 to 75 portions of kanamycin, 0.02 to 20 portions of procaine and 5 to 100 portions of fish liver oil, or 0.1 to 57 portions of amikacin, 0.02 to 38 portions of procaine and 5 to 100 portions of fish liver oil. The medicament has the advantages of low cost, stable medicine effect, no pain in the process of therapy, short course of treatment, rapid restore, obvious therapeutic effect and no toxic or side effect on human bodies in clinical experiments. In addition, the medicament is directly spread on a wound surface without needing special treatment. The medicament is fully affirmed by patients.
PURPOSE: The most common cause of cerebral vasospasm is subarachnoid hemorrhage, less frequently it occurs after trauma, infection, and tumor resection. Vasospasm in children is rare and has not been systematically investigated in posterior fossa surgery.
METHODS: The authors undertook a single-center retrospective study of all the pediatric patients who underwent surgery on the posterior fossa and presented with postoperative symptomatic vasospasm in the period from January 2018 to February 2024. Subsequently, a systematic literature review in accordance with the PRISMA guidelines was performed in the PubMed and Scopus databases to identify the published papers on symptomatic vasospasm after posterior fossa surgery in children.
RESULTS: Of the 178 patients who underwent surgery on the posterior fossa, only one patient was diagnosed with symptomatic diffuse vasospasm on postoperative day 21. The systematic literature review provided further 9 children. The underlying pathology comprised 8 intra-axial lesions with 4 medulloblastomas, 1 schwannoma in the medulla oblongata, 1 pilocytic astrocytoma, 1 primitive neuroectodermal tumor, and 1 arteriovenous malformation. The extra-axial lesions were 1 hypoglossal schwannoma and 1 oculomotor nerve schwannoma.
CONCLUSION: Iatrogenic symptomatic vasospasm after posterior fossa surgery in children is a rare complication with an outcome ranging from complete recovery to the death of the patient. It is important for all staff involved in the care of patients undergoing surgery on the posterior fossa to be aware of this rare postoperative complication. The small number of patients affected does not allow a substantiated conclusion to be drawn about predictive risk factors.
All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg \[2×CQ 300 mg\] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily \[OD\] orally; OR, 620 mg \[4×CQ 155 mg\] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily \[OD\] orally). Tafenoquine 300mg (2×TQ 150 mg) will be given as a single oral dose on Day 1 or Day 2. Primaquine matching placebo will be given OD orally beginning on Day 1 or Day 2 and continue for 14 days total dosing. All subjects will be followed-up till 180 days.
AIMS: To model and assess the cost-effectiveness of CT-based fractional flow reserve (FFRct) for a population of low to intermediate risk patients for coronary artery disease (CAD) presenting to the emergency department (ED) with acute chest pain.
METHODS AND RESULTS: Using a decision tree model with a 1 year time horizon and from a health care perspective, two diagnostic pathways using FFRct are compared to current clinical routine combining coronary computed tomography angiography (CCTA) with an exercise test. Model data are drawn from the literature and nationally reported data. Outcomes are assessed as the number of avoided invasive coronary angiographies (ICAs) showing no obstructive CAD and quality of life (QoL) in a theoretical cohort of 1000 patients. Sensitivity analyses are performed to test the robustness of the results. Determining FFRct when CCTA is inconclusive is a cost-effective and dominant strategy with a potential saving of 198€/patient, 154 avoided unnecessary ICA showing no obstructive CAD (uICA)/1000 patients and an average improvement in QoL of 0.008 QALY/patient. With an additional 574€/patient, 8 avoided uICA/1000 patients and an improvement in QoL of 0.001 QALY/patient, a strategy where FFRct is always performed is cost-effective only when considering high cost-effectiveness thresholds.
CONCLUSIONS: For patients presenting to the ED with acute chest pain and a low to intermediate pre-test probability of CAD, a diagnostic strategy where FFRct is determined after an inconclusive CCTA is cost-effective. Clinical trials investigating both sensitivity and specificity of FFRct, as well as QoL associated with the use of this technology in this setting are warranted.
Sickle cell disease (SCD) is associated with arthropathy. Arthropathy causes pain which may require periarticular corticosteroid injection therapy. There is inadequate data about the suitability of steroid therapy in SCD patients. This prospective observational study examines the efficacy, and safety of periarticular steroid injections in SCD patients.

This is a cohort study of adult patients undergoing pain management at a pain clinic in Canada. Data collection includes patient's gender, age, race, smoking history, alcohol intake, analgesic usage, numeric pain score, sleep quality score, limb joint injections, post-injection analgesia, and post-injection complication. Pain is measured using numeric pain rating scale. Sleep quality is measured using the Likert Sleep scale. A change in the pain or sleep scores by 2-points is considered significant. Data are analyzed with IBM® SPSS® Statistics 25; using Student's t-test, ANOVA, Pearson Chi-square test, and regression analysis. P-value \<0.05 is considered significant.
What is vision's role in driving early word production? To answer this, we assessed parent-report vocabulary questionnaires administered to congenitally blind children (N = 40, Mean age = 24 months [R: 7-57 months]) and compared the size and contents of their productive vocabulary to those of a large normative sample of sighted children (N = 6574). We found that on average, blind children showed a roughly half-year vocabulary delay relative to sighted children, amid considerable variability. However, the content of blind and sighted children's vocabulary was statistically indistinguishable in word length, part of speech, semantic category, concreteness, interactiveness, and perceptual modality. At a finer-grained level, we also found that words' perceptual properties intersect with children's perceptual abilities. Our findings suggest that while an absence of visual input may initially make vocabulary development more difficult, the content of the early productive vocabulary is largely resilient to differences in perceptual access. RESEARCH HIGHLIGHTS: Infants and toddlers born blind (with no other diagnoses) show a 7.5 month productive vocabulary delay on average, with wide variability. Across the studied age range (7-57 months), vocabulary delays widened with age. Blind and sighted children's early vocabularies contain similar distributions of word lengths, parts of speech, semantic categories, and perceptual modalities. Blind children (but not sighted children) were more likely to say visual words which could also be experienced through other senses.
PURPOSE:To obtain a polypeptide usable as a preventing or a therapeutic agent for ateliosis or abnormal proliferation of a neuron or a hematopoietic cell, hypofunction or hyperfunction of the immunological or nerve system or tumor or inflammatory diseases, etc. CONSTITUTION:The new polypeptide is produced by a cell strain of a human glioblastoma and composed of 253 amino acids. The method for producing the polypeptide and the DNA capable of coding this polypeptide. The fragment is capable of selectively hybridizing with the DNA sequence thereof. The replication or expression vector is composed of this DNA and the host cell is transformed with this vector. The antibody against this polypeptide is provided and the pharmaceutical composition contains the polypeptide or the antibody.
Aspects of the present disclosure relate to a dispensing device capable of storing and dispensing strips/films. The dispensing device can deliver films of preselected length providing a predetermined medication dose, when required by user making it convenient for user to store, carry and administer the required doses. The dispensing device can allow retrieval and application of strips with minimal manipulation, permitting single-hand operation, thereby maintaining sterility of the strips/films. The dispenser can hold a pharmaceutical or herbal formulation on a suitable delivery material such as a film in roll form or cartridge form. The roll or the cartridge can last for number of doses sufficient for few days thus enabling a user to carry his medicine requirement in a convenient manner. Further, it provides hygienic storage and offers consistent and precise dispensing without user having to touch the thin film strip.